İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023

The level of dementia biomarkers in type 2 diabetes mellitus

Cukurova Medical Journal

YÖKSİS OpenAlex Açık erişim · diamond JCR Q3 TR Index Atıf 0 Yüzdelik 14.8% FWCI 0.0
Yıl
2023
ISSN
2602-3032
Tür
article

Veri kaynağı ayrımı

  • YÖKSİS YÖKSİS makale kaydı
  • OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)

Özet

İngilizce (OpenAlex)

Purpose: Like Alzheimer's disease, a disease of the aging world, and metastasis in cancer, it is very important to elucidate the etiology of Type 2 diabetes, which causes tissue and organ damage by systematically spreading throughout. In this study, we aimed to examine whether markers used as biomarkers in Alzheimer's pathogenesis are effective in the pathogenesis of diabetes. Materials and Methods: In our study, 30 type 2 diabetics, 30 type 2 diabetics individuals with the risk of dementia as a result of mini-mental test, and 28 healthy individuals aged 50-70 years were included, and brain-derived neurotrophic factor (BDNF), dual-specificity tyrosine-regulated kinase 1 (DYRK1A), Tau, fatty acid binding proteins 7 (FABP7) levels were measured from plasma samples. Results: There was a significant difference between the diabetes group with a high risk of dementia (MMSE < 24) and the other groups in Tau, and FABP7 levels, but no significant differences were found in BDNF and DYRK1A levels. Conclusion: These biomarkers might be used to diagnose Alzheimer's disease in patients with T2D and at risk of dementia before resorting to other more expensive and invasive diagnostic methods.

Konular

  • Neurological Disease Mechanisms and Treatments
  • Alzheimer's disease research and treatments
  • Neurological Disorders and Treatments

Birincil konu Neurological Disease Mechanisms and Treatments

Yazarlar

  1. LÜTFİYE ÖZPAK
  2. MURAT ŞAHİN
  3. İBRAHİM SEYFETTİN ÇELİK
  4. BEKİR MEHMET KELLECİ
  5. MUSTAFA ÇELİK KAHRAMANMARAŞ SÜTÇÜ İMAM ÜNİVERSİTESİ